Halki Diabetes Remedy

Natural Ways to Treat Diabetes

Get Instant Access

  1. Flegal, KM, Carroll, MD, Ogden CL, and Johnson, CL, Prevalence and trends in obesity among US adults, 1999-2000, J. Am. Med. Assoc., 288:1723-1727, 2002.
  2. Bray, GA, Health hazards of obesity, Endocrinol. Metab. Clin. North. Am., 25:907-919, 1996.
  3. MacDonald, IA, Energy expenditure in humans: the influence of activity, diet and sympathetic nervous system, in Clinical Obesity, Kopelman, PG and Stock, MJ, Eds., Blackwell Science, Oxford, U.K., 1998, p. 112-128.
  4. Williams, G, Bing, C, Cai, XJ, Harrold, JA, King, PJ, and Liu, XH, The hypothalamus and the control of energy homeostasis: different circuits, different purposes, Physiol. Behav, 74:683-701, 2001.
  5. Grill, HJ and Smith, GP, Cholecystokinin decreases sucrose intake in chronic decer-ebrate rats, A.J.P., 254:R853-R856, 1988.
  6. Tatemoto, K, Neuropeptide Y: complete amino acid sequence of the brain peptide, Proc. Natl. Acad. Sci. U.S.A., 79:5485-5489, 1982.
  7. Kalra, SP, Dube, MG, Pu, S, Xu, B, Horvath, TL, and Kalra, PS, Interacting appetite-regulating pathways in the hypothalmic regulation of body weight, Endocrine Rev., 20:68-100, 1999.
  8. Wynne, K, Stanley, S, and Bloom, SR, The gut and regulation of body weight, J. Clin. Endocrinol. Metab., 89:2576-2582, 2004.
  9. Batterham, RL, Cowley, MA, Small, CJ, Herzog, H, Cohen, MA, Dakin, CL, Wren, AM, Brynes, AE, Low, MJ, Ghatei, MA, Cone, RD, and Bloom, SR, Gut hormone PYY (3-36) physiologically inhibits food intake, Nature, 418:650-654, 2002.
  10. Goldstone, AP, Unmehopa, UA, Bloom, SR, and Swaab, DF, Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects, J. Clin. Endocrinol. Metab., 87:927-937, 2002.
  11. Rossi, M, Kim, MS, Morgan, DG, Small, CJ, Edwards, CM, Sunter, D, Abusana, S, Goldstone, AP, Russell, SH, Stanley, SA, Smith, DM, Yagaloff, K, Ghatei, MA, and Bloom, SR, A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of a-melanocyte stimulating hormone in vivo, Endocrinology, 139:4428-4431, 1998.
  12. Small, CJ, Kim, MS, Stanley, SA, Mitchell, JR, Murphy, K, Morgan, DG, Ghatei, MA, and Bloom, SR, Effects of chronic central nervous system administration of Agouti-related protein in pair-fed animals, Diabetes, 50:248-254, 2001.
  13. Nakazato, M, Murakami, N, Date, Y, Kojima, M, Matsuo, H, Kangawa, K, and Matsukura, S, A role for ghrelin in the central regulation of feeding, Nature, 409:194-198, 2001.
  14. De Lecea, L, Kilduff, TS, Peyron, C, Gao, X, Foye, PE, Danielson, PE, et al., The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity, Proc. Natl. Acad. Sci. U.S.A., 95:322-327, 1998.
  15. Sakurai, T, Amemiya, A, Ishil, M, Matsuzaki, I, Chemelli, RM, Tanaka, H, et al., Orexins and orexin receptors: A family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior, Cell, 92:573-585, 1998.
  16. Nishino, S, The hypocretin/orexin system in health and disease, Biol. Psychiatr., 54:87-95, 2003.
  17. Willie, JT, Chemelli, RM, Sinton, CM, and Yanagisawa, M, To eat or to sleep? Orexin in the regulation of feeding and wakefulness, Annu. Rev. Neurosci., 24:429-458, 2001.
  18. Chemelli, RM, Willie, JT, Sinton, CM, Elmquist, JK, Scammell, T, Lee, C, et al., Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation, Cell, 98:437-451, 1999.
  19. Lin, L, Faraco, J, Li, R, Kadotani, H, Rogers, W, Lin, X, et al., The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene, Cell, 98:365-376, 1999.
  20. Nishino, S, Ripley, B, Overeem, S, Nevsimalova, S, Lammers, GJ, Vankova, J, et al., Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy, Ann. Neurol., 50:381-388, 2001.
  21. Taheri, S, Zeitzer, JM, and Mignot, E, The role of hypocretins (orexins) in sleep regulation and narcolepsy, Ann. Rev. Neurosci., 25:283-313, 2002.
  22. Neary, NM, Goldstone, AP, and Bloom, SR, Appetite regulation: from gut to the hypothalamus, Clin. Endocrinol. (Oxf), 60:153-160, 2004.
  23. Schwartz, MW, Woods, SC, Porte, D, Seeley, RJ, and Baskin, DG, Central nervous system control of food intake, Nature, 404:661-671, 2000.
  24. Huszar, D, Lynch, CA, Fairchild-Huntress, V, Dunmore, JH, Fang, Q, Beremeier, LR, Gu, W, Kesterson, RA, Boston, BA, Cone, RD, Smith, FJ, Campfield, LA, Burn, P, and Lee, F, Targeted disruption of the melanocortin -4 receptor results in obesity in mice, Cell, 88:131-141, 1997.
  25. Farooqi, IS, Yeo, GS, Keogh, JM, Aminian, S, Jebb, SA, Butler, G, Cheetham, T, and O'Rahilly, S, Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest., 106:271-279, 2000.
  26. Farooqi, IS, Yeo, GS, and O'Rahilly, S, Binge eating as a phenotype of melanocortin 4 receptor gene mutations, N. Engl. J. Med., 348:1096-1103, 2003.
  27. Fehm, HL, Smolnik, R, Kern, W, McGregor, GP, Bickel, U, and Born, J, The melanocortin melanocyte-stimulating hormone/adrenocorticotropin (4-10) decreases body fat in humans, J. Clin. Endocrinol. Metab. 86:1144-1148, 2001.
  28. Cowley, MA, Smart, JL, Rubinstein, M, Gerdan, MG, Diano, S, Horvath, TL, Cone, RD, and Low, MJ, Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus, Nature, 411:480-484, 2001.
  29. Rothman, RB, Vu, N, Wang, X, and Xu, H, Endogenous CART peptide regulates mu opioid and serotonin 5-HT(2A) receptors, Peptides, 3:413-417, 2003.
  30. Cota, D, Marsicano, G, Tschop, M, Grubler, Y, Flachskamm, C, Schubert, M, Auer,

D, Yassouridis, A, Thone-Reineke, C, Ortmann, S, Tomassoni, F, Cervino, C, Nisoli,

E, Linthorst, AC, Pasquali, R, Lutz, B, Stalla, GK, and Pagotto, U, The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis, J. Clin. Invest., 112:423-431, 2003.

  1. Blundell, JE, Serotonon and appetite, Neuropharmacology, 23:1537-1551, 1984.
  2. Tecott, LH, Sun, LM, Akana, SF, Strack, AM, Lowenstein, DH, Dallman, MF, and Julius, D, Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors, Nature 374:542-546, 1995.
  3. Randle, PJ, Kerby, AL, and Espinal, J, Mechanisms decreasing glucose oxidation in diabetes and starvation: Role of lipid fuels and hormones, Diabetes. Metab. Rev., 4:623-638, 1988.
  4. Unger, R, Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications, Diabetes, 44:863-870, 1995.
  5. Laaksonen, DE, Lakka, TA, Lakka, HM, Nyyssonen, K, Rissanen, T, Niskanen, LK, and Salonen, JT, Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men, Diabet. Med., 19:456-464, 2002.
  6. Hotamisligil, GS, Shargill, NS, and Spiegelman, BM, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance, Science, 259:87-91, 1993.
  7. Hotamisligil, GS, Budavari, A, Murray, DL, and Spiegelman, BM, Reduced tyrosine activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-a, J. Clin. Invest, 94:1543-1549, 1994.
  8. Kern, PA, Saghizadeh, M, Ong, JM, Bosch, RJ, Deem, R, and Simsolo, RB, The expression of tumor necrosis factor in adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase, J. Clin. Invest., 95:2111-2119, 1995.
  9. Norman, RA, Bogardus, C, and Ravussin, E, Linkage between obesity and a marker near the tumor necrosis factor-a locus in Pima Indians, J. Clin. Invest., 96:158-162, 1995.
  10. Hotamisligil, GS, Peraldi, P, Budavari, A, Ellis, R, White, MF, and Spiegelman, BM, IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance, Science, 271:665-668, 1996.
  11. Moller, DE, Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes, Trends. Endocrinol. Metab, 11:212-217, 2002.
  12. Grimble, RF, Inflammatory status and insulin resistance, Curr. Opin. Clin. Nutr. Metab. Care, 5:552-559, 2002.
  13. Freeman, DJ, Norrie, J, Caslake, MJ, Gaw, A, Ford, I, Lowe, GD, O'Reilly, DS, Packard, CJ, and Sattar, N, C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study, Diabetes, 51:1596-1600, 2002.
  14. Stefan, N, Vozarova, B, Funahashi, T, Matsuzawa, Y, Weyer, C, Lindsay, RS, Youn-gren, JF, Havel, PJ, Pratley, RE, Bogardus, C, and Tataranni, PA, Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phospho-rylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans, Diabetes, 51:1884-1888, 2002.
  15. Qi, Y, Takahashi, N, Hileman, SM, Patel, HR, Berg, AH, Pajvani, UB, Scherer, PE, and Ahima, RS, Adiponectin acts in the brain to decrease body weight, Nat. Med., 10:524-529, 2004.
  16. Zhang, Y, Proenca, R, Maffei, M, Barone, M, Leopold, L, and Friedman, JM, Positional cloning of the mouse obese gene and its human homologue, Nature, 372:425-432, 1994.
  17. Bado, A, Lavasseur, S, Attoub, S, Kermorgant, S, Laigneau, J-P, Bortoluzzi, M-N, Le Marchand-Brustel, Y, and Lewin, MJM, The stomach as a source of leptin, Nature, 304:790-793, 1998.
  18. Dagogo-Jack, S, Selke, G, Melson, AK, and Newcomer, JW, Robust leptin secretory responses to dexamethasone in obese subjects, J. Clin. Endocrinol. Metab., 82:3230-3233, 1997.
  19. Dagogo-Jack, S, Human leptin regulation and promise in pharmacotherapy, Curr. Drug Targ., 2:181-195, 2001.
  20. Montague, CT, Faroogi, IS, Whitehead, JP, Soos, MA, Rau, H, Wareham, NJ, Sewter, CP, Digby, JE, Mohammed, SN, Hurst, JA, Cheetham, CH, Earley, AR, Barnett, AH, Prins, JB, and O'Rahilly, S, Congenital leptin deficiency is associated with severe early-onset obesity in humans, Nature, 387:903-908, 1997.
  21. Strobel, A, Issad, T, Camoin, L, Ozata, M, and Strosberg, AD, A leptin missense mutation associated with hypogonadism and morbid obesity, Nature, Genet 18:213-215, 1998.
  22. Considine, RV, Considine, EL, Williams, CJ, Nyce, MR, Magosin, SA, Bauer, TL, Rosato, EL, Colberg, J, and Caro, JF, Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity, J. Clin. Invest., 95:2986-2988, 1995.
  23. Halaas, JL, Gajiwala, KS, Maffei, M, Cohen, SL, Chait, BT, Rabinowitz, D, Lallone, RL, Burley, SK, and Friedman, JM, Weight-reducing effects of the plasma protein encoded by the obese gene, Science, 269:543-546, 1995.
  24. Pelleymounter, MA, Cullen, MJ, Baker, MB, Hecht, R, Winters, D, Boone, T, and Collins, F, Effects of the obese gene product on body weight regulation in ob/ob mice, Science, 269:540-543, 1995.
  25. Farooqi, IS, Jebb, SA, Langmack, G, Lawrence, E, Cheetham, CH, Prentice, AM, Hughes, IA, McCamish, MA, and O'Rahilly, S, Effect of recombinant leptin therapy in a child with congenital leptin deficiency, N. Engl. J. Med, 34:879-884, 1999.
  26. Farooqi, IS, Matarese, G, Lord, GM, Keogh, JM, Lawrence, E, Agwu, C, Sanna, V, Jebb, SA, Perna, F, Fontana, S, Lechler, RI, DePaoli, AM, and O'Rahilly, S, Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin defciency, J. Clin. Invest., 110:1093-1103, 2002.
  27. Licinio, J, Caglayan, S, Ozata, M, Yildiz, BO, de Miranda, PB, O'Kirwan, F, et al., Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypog-onadism, and behavior in leptin-deficient adults, Proc. Natl. Acad. Sci. U.S.A., 101:4531-4536, 2004.
  28. Tartaglia, LA, Dembski, M, Weng, X, Deng, N, Culpepper, J, De Vos, R, Richards, GJ, Campfield, LA, Clark, FT, Deeds, J, Muir, C, Sanker, S, Moriarty, A, Moore, KJ, Smutko, JS, Mays, GG, Woolf, EA, Monroe, CA, and Tepper, RI, Identification and expression cloning of a leptin receptor, OB-R, Cell, 83:1263-1271, 1995.
  29. Akaya, K, Ogawa, Y, Isse, N, Okazaki, T, Satoh, N, Masuzaki, H, Mori, K, Tamura, N, Hosoda, K, and Nakao, K, Molecular cloning of the rat leptin receptor isoform complementary DNAs — identification of a missense mutation in Zucker fatty (fa/fa) rats, Biochem. Biophys. Res. Commun., 225:75-83, 1996.
  30. Lee, GH, Proenca, R, Montez, JM, Carroll, KM, Darvishzadeh, JG, Lee, JI, and Friedman, JM, Abnormal splicing of the leptin receptor in diabetic mice, Nature, 379:632-635, 1997.
  31. Vaisse, C, Halaas, JL, Horvath, CM, Darnell, JE, Jr., Stoffel, M, and Friedman, JM, Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice, Nature Genet., 14:95-97, 1996.
  32. Wang, Y, Kuropatwinski, KK, White, DW, Hawley, TS, Hawley, RG, Tartaglia, LA, and Baumann, H, Leptin receptor action in hepatic cells, J. Biol. Chem., 272:16216-16223, 1997.
  33. Stephens, TW, Basinski, M, Bristow, PK, Bue-Valleskey, JM, Burgett, SG, Craft, L, Hale, J, Hoffmann, J, Hsiung, HM, Kriauciunas, A, MacKellar, W, Rosteck, PR, Jr., Schoner, B, Smith, D, Tinsley, FC, Zhang, X-Y, and Heiman, M, The role of neu-ropeptide Y in the antiobesity action of the obese gene product, Nature, 377:530-532, 1995.
  34. Chen, H, Charlat, O, Tartaglia, LA, Woolf, EA, Weng, X, Ellis, SJ, Lakey, ND, Culpepper, J, Moore, KJ, Breitbart, RE, Duyk, GM, Tepper, RI, and Morgenstern, JP, Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice Cell, 84:491-495, 1996.
  35. Phillips, MS, Liu, Q, Hammond, HA, Dugan, V, Hey, PJ, Caskey, CJ, and Hess, JF, Leptin receptor missense mutation in the fatty Zucker rat, Nat. Genet., 13:18-19, 1966.
  36. Clement, K, Vaisse, C, Lahlou, N, Cabrol, S, Pelloux, V, Cassuto, D, Gourmelen, M, Dina, C, Chambaz, J, Lacorte, J-M, Basdevant, A, Bougneres, P, Lebouc, Y, Froguel, P, and Guy-Grand, B, A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction, Nature, 392:398-401, 1998.
  37. Lonnqvist, F, Aener, P, Nordfors, L, and Schalling, M, Overexpression of the obese (ob) gene in adipose tissue of obese subjects, Nat. Med., 1:950-953, 1995.
  38. Hamilton, BS, Paglia, D, Kwan, AYM, and Deitel, M, Increased obese mRNA expression in omental fat cells from massively obese humans, Nat. Med., 1:953-956, 1995.
  39. Considine, RV, Sinha, MK, Heiman, ML, Kriaciunas, A, Stephens, TW, Nyce, MR, Ohannesian, JP, Marco, CC, McKee, LJ, Bauer, TL, and Caro, JF, Serum immunore-active-leptin concentrations in normal-weight and obese humans, N. Engl. J. Med., 334:292-295, 1996.
  40. Schwartz, MW, Peskind, E, Boyko, EJ, and Porte, D, Jr., Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat. Med., 2:589-593,


  1. Blorbaek, C, El-Haschimi, K, Fratz, JD, and Flier, JS, The role of SOCS-3 in leptin signaling and leptin resistance, J. Biol. Chem, 274(42):30059-30065, 1999.
  2. Kamohara, S, Burcelin, R, Halaas, JL, Friedman, JM, and Charron, MJ, Acute stimulation of glucose metabolism in mice by leptin treatment, Nature, 389:374-377,


  1. Barzilai, N and Gupta, G, Interaction between aging and syndrome X: new insights on the pathophysiology of fat distribution, Ann. N.Y. Acad. Sci., 892:58-72, 1999.
  2. Cohen, B, Novick, D, and Rubinstein, M, Modulation of insulin activities by leptin, Science, 274:1185-1188, 1996.
  3. Shimabukuro, M, Koyama, K, Chen, G, Wang, MY, Trieu, F, Lee, Y, Newgard, CB, and Unger, RH, Direct antidiabetic effect of leptin through triglyceride depletion of tissues, Proc. Natl. Acad. Sci. U.S.A., 94:4637-4641, 1997.
  4. Tykodi, G, Askari, H, and Dagogo-Jack, S, Fasting plasma leptin levels predict insulin sensitivity in obese and non-obese humans, Program and Abstracts, 86th Annual Meeting, Endocrine Society, New Orleans, Abstract P2-336, June 2004.
  5. Sinha, MK, Ohannesian, JP, Heiman, ML, Kriauciunas, A, Stephens, TW, Magosin, S, Marco, C, and Caro, JF, Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects, J. Clin. Invest., 97:1344-1347, 1996.
  6. Liu, J, Askari, H, and Dagogo-Jack S, Basal and stimulated plasma leptin in diabetic subjects, Obes. Res., 7:537-544, 1999.
  7. Dagogo-Jack, S, Liu, J, Askari, H, Tykodi, G, and Umamaheswaran, I, Impaired leptin response to glucocorticoid as a chronic complication of diabetes, J. Diabet. Compl., 14:1-6, 2000.
  8. Askari, H, Tykodi, G, and Dagogo-Jack, S, Dynamic leptin responses to glucocorticoid and insulin in lean and obese subjects, Diabetes, 53(Suppl. 2) (Abstr.), A412, 2004.
  9. Askari, H, Liu, J, and Dagogo-Jack, S, Hormonal regulation of human leptin in vivo: effects of hydrocortisone and insulin, Inter. J. Obesity., 24:1254-1259, 2000.
  10. Laferrere, B, Fried, SK, Hough, K, Campbell, SA, Thornton, J, and Pi-Sunyer, FX, Synergistic effects of feeding and dexamethasone on serum leptin levels, J. Clin. Endocrinol. Metab., 83:3742-3745, 1998.

Umamaheswaran, I, Askari, H, Tykodi, G, and Dagogo-Jack, S, Plasma leptin responsiveness to glucocorticoid occurs at physiological doses, and is abolished by fasting, Obes. Res., 11:232-237, 2003.

Oral, EA, Simha, V, Ruiz, E, Andewelt, A, Premkumar, A, Snell, P, Wagner, AJ, DePaoli, AM, Reitman, ML, Taylor, SI, Gorden, P, and Garg, A, Leptin-replacement therapy for lipodystrophy, N. Engl. J. Med.., 346:570-578, 2002. Haynes, WG, Morgan, DA, Walsh, SA, Mark, AL, Sivitz, WI, Receptor-mediated regional sympatheric nerve activation by leptin, J. Clin. Invest., 100:270-278, 1997. Heymsfield, SB, Greenberg, AS, Fujioka, K, Dixon, RM, Kushner, R, Hunt, T, Lubina, JA, Patane, J, Self, B, Hunt, P, and McCamish, M, Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose escalation trial, JAMA, 282(16):1568-1575, 1999.

Kennedy, GC, The role of depot fat in the hypothalmic control of food intake in the rat. Proceedings of the Royal Society of London, B 140:579-592, 1953. Baura, GD, Foster, DM, Porte, D, Jr., Kahn, SE, Bergman, RN, Cobelli, C, and Schwartz, MW, Saturable transport of insulin from plasma into the central nervous system of dog in vivo. A mechanism for regulated insulin delivery to the brain, J. Clin. Invest, 92:1824-1830, 1993.

McLaughlin, CL, Role of peptides from gastrointestinal cells in food intake regulation, J. Anim. Sci., 55(6):1515-1527, 1982.

Brunicardi, FC, Chaiken, RL, Ryan, AS, Seymour, NE, Hoffmann, JA, Lebovitz, HE, Chance, RE, Gingerich, RL, Andersen, DK, and Elahi, D, Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis, J. Clin. Endocrinol. Metab., 81(10):3566-3572, 1996. Larhammer, D, Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide,. Regul. Pept., 65:165-174, 1996.

Kojima, M, Hosoda, H, Date, Y, Nakazato, M, Matsuo, H, and Kangawa, K, Ghrelin is a growth-hormone-releasing acylated peptide from stomach, Nature, 402:656-660, 1999.

Wren, AM, Small, CJ, Ward, HL, Murphy, KG, Dakin, CL, Taheri, S, Kennedy, AR, Roberts, GH, Morgan, DG, Ghatei, MA, and Bloom, SR, The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion, Endocrinology, 141:4325-4328, 2000.

Wren, AM, Seal, LJ, Cohen, MA, Byrnes, AE, Frost, GS, Murphy, KG, Dhillo, WS, Ghatei, MA, and Bloom, SR, Ghrelin enhances appetite and increases food intake in humans, J. Clin. Endocrinol. Metab., 86:5992, 2001.

Cummings, DE, Purnell, JQ, Frayo, RS, Schmidova, K, Wisse, BE, and Weigle, DS, A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans, Diabetes, 50:1714-1719, 2001.

Tschop, M, Weyer, C, Tataranni, PA, Devanarayan, V, Ravussin, E, and Heiman, ML, Circulating ghrelin levels are decreased in human obesity, Diabetes, 50:707-709, 2001.

Nakazato, M, Murakami, N, Date, Y, Kojima, M, Matsuo, H, Kangawa, K, and Matsukura, S, A role for ghrelin in the central regulation of feeding, Nature, 409:194-198, 2001.

Date, Y, Murakami, N, Toshinai, K, Matsukura, S, Nijima, A, Matsuo, H, Kangawa, K, and Nakazato, M, The role of the gastrin afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats, Gastroenterology, 123:1120-1128, 2002.

  1. Batterham, RL, Cowley, MA, Small, CJ, Herzog, H, Cohen, MA, Dakin, CL, Wren, AM, Brynes, AE, Low, MJ, Ghatei, MA, Cone, RD, and Bloom, SR, Gut hormone PYY(3-36) physiologically inhibits food intake, Nature, 418:650-654, 2002.
  2. Batterham, RL, Cohen, MA, Ellis, SM, Le Roux, CW, Withers, DJ, Frost, GS, Ghatei, MA, and Bloom, SR, Inhibition of food intake in obese subjects by peptide YY3-36, N. Engl. J. Med., 349:941-948, 2003.
  3. Turton, MD, O'Shea, D, Gunn, I, Beak, SA, Edwards, CM, Meernan, K, Choi, SJ, Taylor, GM, Heath, MM, Lambert, PD, Wilding, JP, Smith, DM, Ghatei, MA, Herbert, J, and Bloom, SR, A role for glucagon-like peptide-1 in the central regulation of feeding, Nature, 379:69-72, 1996.
  4. Kreymann, B, Williams, G, Ghatei, MA, and Bloom, SR, Glucagon-like peptide-1,7-36: a physiological incretin in man, Lancet, 2:1300-1304, 1987.
  5. Verdich, C, Flint, A, Gutzwiller, JP, Naslund, E, Beglinger, C, Hellstrom, PM, Long, SJ, Morgan, LM, Holst, JJ, and Astrup, A, A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans, J. Clin. Endocrinol. Metab., 86:4382-4389, 2001.
  6. Todd, JF, Wilding, JP, Edwards, CM, Khan, FA, Ghatei, MA, and Bloom, SR, Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus, Eur. J. Clin. Invest., 27:533-536, 1997.
  7. Egan, JM, Cocquet, AR, and Elahi, D, The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes, J. Clin. Endocrinol. Metab., 87:1282-1290, 2002.
  8. Ahren B, Simonsson, E, Larsson, H, Landin-Olsson, M, Torgeirsson, H, Jansson, PA, Sandqvist, M, Bavenholm, P, Efendic, S, Eriksson, JW, Dickinson, S, and Holmes, D, Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes, Diabet. Care, 25:869-875, 2002.
  9. Gibbs, J, Young, RC, and Smith, GP, Cholecystokinin decreases food intake in rats, J. Comput. Physiol. Psychol., 84:488-495, 1973.
  10. Moran, TH, Cholecytoskinin and satiety: current perspectives. Nutrition , 16:858-865, 2000.
  11. Matson, CA, Wiater, MF, Kuijper, JL, and Weigle, DS, Synergy between leptin and cholecystokinin (CCK) to control daily caloric intake, Peptides, 18:1275-1278, 1997.
  12. West, DB, Greenwood, MR, Marshall, KA, and Woods, SC, Lithium chloride, chole-cystokinin and meal patterns: evidence that cholecystokinin suppresses meal size in rats without causing malaise, Appetite, 8:221-227, 1987.
  13. Crawley, JN and Beinfeld, MC, Rapid development of tolerance to the behavioural actions of cholecystokinin, Nature, 302:703-706, 1983.

Was this article helpful?

0 0
Supplements For Diabetics

Supplements For Diabetics

All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.

Get My Free Ebook

Post a comment